2022
Longitudinal monitoring of hair cortisol using liquid chromatography-mass spectrometry to prevent hypercortisolism in patients undergoing glucocorticoid replacement therapy
KOSTOLANSKÁ, Katarína, Helena ŠIPROVÁ, Elis BARTEČKŮ, Jan JUŘICA, Ivan ŘIHÁČEK et. al.Základní údaje
Originální název
Longitudinal monitoring of hair cortisol using liquid chromatography-mass spectrometry to prevent hypercortisolism in patients undergoing glucocorticoid replacement therapy
Autoři
KOSTOLANSKÁ, Katarína (703 Slovensko, domácí), Helena ŠIPROVÁ (203 Česká republika), Elis BARTEČKŮ (203 Česká republika, domácí), Jan JUŘICA (203 Česká republika, domácí), Ivan ŘIHÁČEK (203 Česká republika), Eva TÁBORSKÁ (203 Česká republika, domácí), Miroslav SOUČEK (203 Česká republika) a Ondřej PEŠ (203 Česká republika, garant, domácí)
Vydání
THERAPEUTIC DRUG MONITORING, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2022, 0163-4356
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30202 Endocrinology and metabolism
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.500
Kód RIV
RIV/00216224:14110/22:00125625
Organizační jednotka
Lékařská fakulta
UT WoS
000793999100013
Klíčová slova anglicky
LC MS; hair cortisol; longitudinal; substitution therapy; Bayes modeling
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 3. 4. 2023 09:01, Mgr. Tereza Miškechová
Anotace
V originále
Objective: Currently available methods for endogenous cortisol monitoring in patients with hormonal insufficiency rely on measurements of plasma levels only at a single time point; thus, any kind of chronic exposure to cortisol is challenging to evaluate as it requires collecting samples at different time points. Hair cortisol levels acquired longitudinally better reflected chronic exposure (both cortisol synthesis and deposition) and may significantly contribute to better outcomes in glucocorticoid replacement therapies. Design: Twenty-two patients on cortisol substitution therapy were monitored for plasma, urinary, and hair cortisol levels for 18 months to determine whether hair cortisol may serve as a monitoring option for therapy setting and adjustment. Methods: Plasma and urinary cortisol levels were measured using standardized immunoassay methods, and segmented (∼ 1 cm) hair cortisol levels were monitored by liquid chromatography coupled to mass spectrometry. A log-normal model of the changes over time was proposed, and Bayesian statistics were used to compare plasma, urinary, and hair cortisol levels over 18 months. Results and Conclusions: Hair cortisol levels decreased over time in patients undergoing substitutional therapy. The residual variance of hair cortisol in comparison to plasma or urinary cortisol levels was much lower. Thus, longitudinal monitoring of hair cortisol levels could prove beneficial as a non-invasive tool to reduce the risk of overdosing and improve the overall patient health.
Návaznosti
MUNI/A/1090/2021, interní kód MU |
| ||
MUNI/A/1266/2020, interní kód MU |
| ||
ROZV/28/LF11/2020, interní kód MU |
| ||
ROZV/28/LF/2020, interní kód MU |
|